Longevity treatments extend life but affect variation in age-at-death

A key goal in aging research is not just to extend life, but to ensure more people live longer and healthier lives with less variation in age-at-death; a concept known as "squaring the survival curve." Using a recent meta-analysis, Dr Tahlia Fulton and Associate Professor Alistair Senior from the University of Sydney School of Life and Environmental Sciences re-examined how dietary restriction and two related drugs, rapamycin and metformin, affect variation in age-at-death in vertebrates.

While two of the treatments increased average lifespan, all three increased variance. This means current lifespan-extending interventions do not "square the survival curve". Instead, the gains in average lifespan are matched by proportional increases in variability.

Dr Fulton said: "These approaches can make animals live longer, but the benefits aren't shared equally. Without more information, the outcome looks like a biological lottery. We're working to understand why, so future longevity science helps everyone."